GICS Sector : Healthcare
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States.It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.The company was incorporated in 2016 and is based in Los Altos, California. Show Full description
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Dec -01
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Nov -25
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Nov -13
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Nov -12
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Nov -03
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Oct -31
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
Oct -30
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
Oct -28
Unicycive Therapeutics' novel therapies drive 9.27% growth, fueled by increasing demand for innovative treatments, strategic partnerships, and expanding pipeline of rare disease therapies. Strong R&D investments, favorable regulatory environments, and growing awareness of rare genetic disorders also contribute to this growth.
A novel, orally bioavailable, small molecule inhibitor of soluble epoxide hydrolase (sEH) for the treatment of various inflammatory diseases
A novel, orally bioavailable, small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for the treatment of autoimmune diseases
A novel, orally bioavailable, small molecule inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of cancer
Unicycive Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Unicycive Therapeutics, Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.
Unicycive Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.
Unicycive Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the market and the ease of entry.
Unicycive Therapeutics, Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | -27.05% |
| Debt Cost | 10.11% |
| Equity Weight | 127.05% |
| Equity Cost | 17.40% |
| WACC | 19.37% |
| Leverage | -21.29% |
Value: 9.0
Growth: 6.1
Quality: 6.2
Yield: 0.0
Momentum: 1.0
Volatility: 2.7
1-Year Total Return ->
Value: 9.6
Growth: 6.9
Quality: 5.2
Yield: 0.0
Momentum: 0.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.4
Growth: 4.6
Quality: 3.6
Yield: 0.0
Momentum: 6.5
Volatility: 0.7
1-Year Total Return ->
Value: 1.0
Growth: 7.9
Quality: 6.1
Yield: 0.0
Momentum: 2.0
Volatility: 3.7
1-Year Total Return ->
Value: 7.8
Growth: 4.2
Quality: 3.2
Yield: 0.0
Momentum: 1.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.4
Growth: 0.3
Quality: 3.2
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->